Advertisement
Advertisement
NKTR
Nektar Therapeutics
70.70
USDSponsored
-1.86
-2.57%
Mar 06, 16:59 UTC -4
Closed
Pre-Market
68.29
-2.41
-3.40%
NKTR Earnings Reports
Positive Surprise Ratio
NKTR beat 32 of 40 last estimates.
80%
Next Report
In 3 Days
Date of Next Report
Mar 12, 2026
Estimate for Q4 25 (Revenue/ EPS)
$10.61M
/-$2.52
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
-63.63%
/+5.00%
Nektar Therapeutics earnings per share and revenue
On --, NKTR reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 10 analysts forecast an EPS of -2.52 USD, with revenue projected to reach 10.61 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
Profound Medical Corp. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.27
Surprise
-0.26%
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-Actual
-$0.01
Surprise
-
Stevanato Group S.p.A.
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.17
Actual
$0.18
Surprise
+4.55%
FAQ
What were Nektar Therapeutics's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Nektar Therapeutics reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Nektar Therapeutics's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Nektar Therapeutics expected to report next?
The next earning report is scheduled for Mar 12, 2026.
What are the forecasts for Nektar Therapeutics's next earnings report?
Based on 10
analysts, Nektar Therapeutics is expected to report EPS of -$2.52 and revenue of $10.61M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement